Osteosarcoma (OS) is a primary bone malignancy characterized by an aggressive nature, limited treatment options, low survival rate, and poor patient prognosis. Conditionally replicative adenoviruses (CRAds) armed with immune checkpoint inhibitors hold great potential for enhanced therapeutic efficacy. The present study aims to investigate the anti-tumor efficacy of CAV2-AU-M2, a CAV2-based CRAd armed with an anti-PD-1 single-domain antibody (sdAb), against OS cell lines . The infection, conditional replication, cytopathic effects, and cytotoxicity of CAV2-AU-M2 were tested in four different OS cell lines in two-dimensional (2D) and three-dimensional (3D) cell cultures. CAV2-AU-M2 showed selective replication in the OS cells and induced efficient tumor cell lysis and death. Moreover, CAV2-AU-M2 produced an anti-PD-1 sdAb that demonstrated effective binding to the PD-1 receptors. This study demonstrated the first CRAd armed with an anti-PD-1 sdAb. This combined approach of two distinct immunotherapies is intended to enhance the anti-tumor immune response in the tumor microenvironment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10886739 | PMC |
| http://dx.doi.org/10.3390/cells13040351 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing the Efficacy of Breast Cancer Immunotherapy Using a Smac-Armed Oncolytic Virus.
Cancers (Basel)
September 2024
Department of Chemistry, Georgia State University, Atlanta, GA 30302, USA.
It has been shown that the response rate of TNBC is dependent on the level of PD-L1 and the tumor microenvironment (TME). Approaches that alter the TME can improve the efficacy of ICIs. : We have engineered a Smac-armed oncolytic virus by inserting a Smac transgene into the genome of a vesicular stomatitis virus to generate VSV-S.
View Article and Find Full Text PDFImproved antitumor effectiveness of oncolytic HSV-1 viruses engineered with IL-15/IL-15Rα complex combined with oncolytic HSV-1-aPD1 targets colon cancer.
Sci Rep
October 2024
School of Pharmacy, Yantai University, Yantai, 264005, Shandong, China.
Article Synopsis
- Oncolytic virotherapy is a new cancer treatment strategy that uses modified viruses to trigger immune responses specifically against tumors, like the novel oncolytic virus (oHSV1-IL15B) developed from herpes simplex virus-1 (HSV-1) for colon cancer treatment.
- In experiments with mice, oHSV1-IL15B demonstrated significant tumor-fighting effects, especially when combined with another oncolytic virus (oHSV-1-aPD1), resulting in better tumor inhibition and longer survival rates compared to using these treatments alone.
- The study revealed that the combination therapies increased the presence of key immune cells (CD8 and CD4 T cells) and improved the tumor's immune environment, suggesting that combining
Enhanced therapeutic efficacy for glioblastoma immunotherapy with an oncolytic herpes simplex virus armed with anti-PD-1 antibody and IL-12.
Mol Ther Oncol
June 2024
Shenzhen International Institute for Biomedical Research, 1301 Guan-Guang Road, Building 1-B, Silver Star Hi-tech Industrial Park, Longhua District, Shenzhen 518110, China.
Glioblastoma is the most common and aggressive malignant brain tumor and has limited treatment options. Hence, innovative approaches are urgently needed. Oncolytic virus therapy is emerging as a promising modality for cancer treatment due to its tumor-specific targeting and immune-stimulatory properties.
View Article and Find Full Text PDFOncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
J Immunother Cancer
April 2024
Department of Pharmaceutical and Biomedical Sciences, California Northstate University College of Pharmacy, Elk Grove, California, USA
Article Synopsis
- Glioblastoma (GBM) is a deadly brain tumor with limited treatment options, primarily driven by a subpopulation of cancer stem-like cells that resist therapies.
- Oncolytic herpes simplex virus (oHSV), particularly talimogene laherparepvec, has shown promise in targeting cancer cells and inducing immune responses, yet its application in GBM remains under-explored.
- A new approach using G47Δ-mIL2, an oHSV designed to locally express interleukin 2 (IL-2), was found to improve survival in mouse GBM models without causing the systemic side effects typically associated with IL-2 treatment.
Successful treatment of paediatric refractory Hodgkin lymphoma with immunotherapy - A case report and literature review.
Acta Paediatr
July 2024
Paediatric Oncology Unit, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
Aim: To describe a rare case of primary refractory Hodgkin lymphoma nodular sclerosis syncytial variant in a child and review immunotherapy in relapsed/refractory Hodgkin lymphoma.
Methods: We described the treatment course of a child with primary refractory classic Hodgkin lymphoma and discussed different options for salvage therapy, with an emphasis on immunotherapy. We searched PubMed for all published clinical trials investigating immunotherapy in classic Hodgkin lymphoma written in English until 31 June, 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!